{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:16:14Z","timestamp":1792548974692,"version":"4.5.0"},"reference-count":64,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The increased use of gabapentinoids has been most pronounced in older people who are also susceptible to hip fractures.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate the overall association between gabapentinoids and the risk of hip fractures and the stratified association across age groups, frailty status, and history of chronic kidney disease.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This was a case-case-time-control study in patients hospitalized for hip fracture in Victoria, Australia, between March 1, 2013, and June 30, 2018, with at least 1 prescription for a gabapentinoid before fracture. Conditional logistic regression was used to estimate the odds ratio (OR) and 95% CI for gabapentinoid dispensing in the index (1-60 days prefracture) compared with the reference (121-180 days prefracture) period. To adjust for the underlying time trend in gabapentinoid use, each index case was matched with up to 5 controls, selected from future cases of the same age and sex. Subgroup analyses were conducted in subgroups with or without chronic kidney disease (CKD), frailty scores less than 5, and frailty scores 5 and above. Frailty was computed using the Hospital Frailty Risk Score (HFRS). Data were analyzed from November 2023 to April 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Gabapentinoids (pregabalin or gabapentin).<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measure<\/jats:title>\n Hip fracture.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 28\u202f293 patients hospitalized for hip fractures, 2946 (1752 [59.5%] aged \u226580 years; 2099 [71.2%] female) were dispensed a gabapentinoid before hip fracture. Gabapentinoid dispensing was associated with increased odds of hip fractures (OR, 1.96; 95% CI, 1.66-2.32). After adjusting for the exposure-time trend and concomitant use of other central nervous system medications, the odds of hip fractures remained elevated (OR, 1.30; 95% CI, 1.07-1.57). The association between gabapentinoid dispensing and hip fracture was higher in patients with HFRS 5 and above (OR, 1.75; 95% CI, 1.31-2.33) and CKD (OR, 2.41; 95% CI, 1.65-3.52).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and relevance<\/jats:title>\n In this case-case-time-control study of Australian residents hospitalized for hip fracture, gabapentinoid use was associated with an increased risk of hip fractures, especially in patients who were frail or had chronic kidney disease. In addition to the known risk associated with kidney impairment, frailty status may be an important risk factor when considering use of gabapentinoids.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.44488","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:37:04Z","timestamp":1731497824000},"page":"e2444488","source":"Crossref","is-referenced-by-count":27,"title":["Gabapentinoids and Risk of Hip Fracture"],"prefix":"10.1001","volume":"7","author":[{"given":"Miriam T. Y.","family":"Leung","sequence":"first","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin P.","family":"Turner","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia"},{"name":"Faculty of Pharmacy, University of Montreal, Quebec City, Quebec, Canada"},{"name":"Centre de Recherche, Institut Universitaire de G\u00e9riatrie de Montr\u00e9al, Montr\u00e9al, Qu\u00e9bec, Canada"},{"name":"Faculty of Pharmacy, Laval University, Quebec City, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Marquina","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni","family":"Ilom\u00e4ki","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia"},{"name":"Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Tran","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Austin Health, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Simon","family":"Bell","sequence":"additional","affiliation":[{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Melbourne, Australia"},{"name":"Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia"},{"name":"Faculty of Health Sciences, University of Eastern Finland, Kuopio, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"issue":"1","key":"zoi241271r1","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.1038\/s41467-023-40637-8","article-title":"Gabapentinoid consumption in 65 countries and regions from 2008 to 2018: a longitudinal trend study.","volume":"14","author":"Chan","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"zoi241271r2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1370\/afm.3052","article-title":"Update to gabapentinoid use in the United States, 2002-2021.","volume":"22","author":"Johansen","year":"2024","journal-title":"Ann Fam Med"},{"key":"zoi241271r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100579","article-title":"Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study.","volume":"27","author":"Ashworth","year":"2023","journal-title":"Lancet Reg Health Eur"},{"issue":"1","key":"zoi241271r4","doi-asserted-by":"publisher","DOI":"10.3399\/bjgpopen20X101120","article-title":"Pregabalin prescribing patterns in Australian general practice, 2012-2018: a cross-sectional study.","volume":"5","author":"Schaffer","year":"2021","journal-title":"BJGP Open"},{"issue":"5","key":"zoi241271r7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jamainternmed.2019.0086","article-title":"A clinical overview of off-label use of gabapentinoid drugs.","volume":"179","author":"Goodman","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"2","key":"zoi241271r8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1056\/NEJMp0808659","article-title":"The Neurontin legacy\u2013marketing through misinformation and manipulation.","volume":"360","author":"Landefeld","year":"2009","journal-title":"N Engl J Med"},{"issue":"16","key":"zoi241271r9","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1007\/s11606-023-08250-z","article-title":"Central nervous system-active prescriptions in older veterans: trends in prevalence, prescribers, and high-risk populations.","volume":"38","author":"Burke","year":"2023","journal-title":"J Gen Intern Med"},{"issue":"2","key":"zoi241271r10","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/2049463720912496","article-title":"Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice.","volume":"14","author":"Chincholkar","year":"2020","journal-title":"Br J Pain"},{"issue":"1","key":"zoi241271r11","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/papr.12146","article-title":"A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain.","volume":"15","author":"Freynhagen","year":"2015","journal-title":"Pain Pract"},{"issue":"6","key":"zoi241271r12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007938.pub4","article-title":"Gabapentin for chronic neuropathic pain in adults.","volume":"6","author":"Wiffen","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"zoi241271r13","doi-asserted-by":"publisher","first-page":"147","DOI":"10.2165\/11596880-000000000-00000","article-title":"Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization.","volume":"30","author":"Budhia","year":"2012","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"zoi241271r14","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1007\/s11657-023-01254-6","article-title":"Hip fracture incidence and post-fracture mortality in Victoria, Australia: a state-wide cohort study.","volume":"18","author":"Leung","year":"2023","journal-title":"Arch Osteoporos"},{"issue":"1","key":"zoi241271r15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-023-06907-3","article-title":"Global burden of hip fracture: The Global Burden of Disease Study.","volume":"35","author":"Feng","year":"2024","journal-title":"Osteoporos Int"},{"issue":"9","key":"zoi241271r16","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1111\/bcp.15798","article-title":"Deprescribing interventions for gabapentinoids in adults: a scoping review.","volume":"89","author":"Anderson","year":"2023","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"zoi241271r17","doi-asserted-by":"publisher","first-page":"174","DOI":"10.18773\/austprescr.2017.055","article-title":"Prescribing for frail older people.","volume":"40","author":"Hilmer","year":"2017","journal-title":"Aust Prescr"},{"issue":"1-2","key":"zoi241271r18","first-page":"24","article-title":"Prescribing for older people with chronic renal impairment.","volume":"42","author":"Bell","year":"2013","journal-title":"Aust Fam Physician"},{"issue":"4","key":"zoi241271r19","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/imj.15759","article-title":"Frailty in chronic kidney disease: challenges in nephrology practice. A review of current literature.","volume":"53","author":"Kennard","year":"2023","journal-title":"Intern Med J"},{"issue":"10206","key":"zoi241271r20","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1016\/S0140-6736(19)31786-6","article-title":"Frailty: implications for clinical practice and public health.","volume":"394","author":"Hoogendijk","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"zoi241271r21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1093\/gerona\/62.7.744","article-title":"Frailty and risk of falls, fracture, and mortality in older women: the study of osteoporotic fractures.","volume":"62","author":"Ensrud","year":"2007","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"1","key":"zoi241271r22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1093\/gerona\/glab102","article-title":"Mortality, falls, and fracture risk are positively associated with frailty: a SIDIAP cohort study of 890?000 patients.","volume":"77","author":"Middleton","year":"2022","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"12","key":"zoi241271r23","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1007\/s00198-014-2828-9","article-title":"A frailty index predicts 10-year fracture risk in adults age 25 years and older: results from the Canadian Multicentre Osteoporosis Study (CaMos).","volume":"25","author":"Kennedy","year":"2014","journal-title":"Osteoporos Int"},{"issue":"1","key":"zoi241271r24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12891-017-1403-x","article-title":"An overview of osteoporosis and frailty in the elderly.","volume":"18","author":"Li","year":"2017","journal-title":"BMC Musculoskelet Disord"},{"issue":"8","key":"zoi241271r25","doi-asserted-by":"publisher","first-page":"W163","DOI":"10.7326\/0003-4819-147-8-200710160-00010-w1","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration.","volume":"147","author":"Vandenbroucke","year":"2007","journal-title":"Ann Intern Med"},{"issue":"4","key":"zoi241271r26","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s00198-023-06974-6","article-title":"Trajectories of oral bisphosphonate use after hip fractures: a population-based cohort study.","volume":"35","author":"Leung","year":"2024","journal-title":"Osteoporos Int"},{"key":"zoi241271r27","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae272","article-title":"Effect of oral bisphosphonate drug holiday on mortality following hip fracture.","author":"Leung","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"zoi241271r28","doi-asserted-by":"publisher","first-page":"2136","DOI":"10.1136\/bmj.p2136","article-title":"Future-case control crossover analysis for adjusting bias in case crossover studies.","volume":"382","author":"Huang","year":"2023","journal-title":"BMJ"},{"issue":"4","key":"zoi241271r29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/EDE.0b013e31821d09cd","article-title":"Future cases as present controls to adjust for exposure trend bias in case-only studies.","volume":"22","author":"Wang","year":"2011","journal-title":"Epidemiology"},{"issue":"2","key":"zoi241271r30","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events.","volume":"133","author":"Maclure","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"24","key":"zoi241271r31","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1001\/jama.2018.6537","article-title":"Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"319","author":"Viswanathan","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"zoi241271r32","doi-asserted-by":"publisher","first-page":"3743","DOI":"10.3390\/nu12123743","article-title":"Undernutrition, sarcopenia, and frailty in fragility hip fracture: advanced strategies for improving clinical outcomes.","volume":"12","author":"Inoue","year":"2020","journal-title":"Nutrients"},{"issue":"5","key":"zoi241271r33","doi-asserted-by":"publisher","first-page":"e614","DOI":"10.1097\/j.pain.0000000000002433","article-title":"Trajectories of pregabalin use and their association with longitudinal changes in opioid and benzodiazepine use.","volume":"163","author":"Schaffer","year":"2022","journal-title":"Pain"},{"issue":"10","key":"zoi241271r34","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1093\/aje\/kww079","article-title":"Persistent user bias in case-crossover studies in pharmacoepidemiology.","volume":"184","author":"Hallas","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"9","key":"zoi241271r35","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1002\/pds.5649","article-title":"Evaluating the use of methods to mitigate bias from non-transient medications in the case-crossover design: a systematic review.","volume":"32","author":"Huang","year":"2023","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"zoi241271r36","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1093\/oxfordjournals.aje.a113439","article-title":"On the need for the rare disease assumption in case-control studies.","volume":"116","author":"Greenland","year":"1982","journal-title":"Am J Epidemiol"},{"issue":"10132","key":"zoi241271r37","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study.","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"issue":"7","key":"zoi241271r39","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults.","volume":"71","author":"By the 2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"zoi241271r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100302","article-title":"Adverse outcomes associated with concurrent gabapentin, opioid, and benzodiazepine utilization: a nested case-control study.","volume":"13","author":"Olopoenia","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"10353","key":"zoi241271r41","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/S0140-6736(22)01472-6","article-title":"Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM): a multicentre, double-blind, randomised crossover trial.","volume":"400","author":"Tesfaye","year":"2022","journal-title":"Lancet"},{"key":"zoi241271r42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/pds.3850","article-title":"Case-only designs for studying the association of antidepressants and hip or femur fracture.","volume":"25","author":"de Groot","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"zoi241271r43","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/pds.3785","article-title":"Psychoactive medicine use and the risk of hip fracture in older people: a case-crossover study.","volume":"24","author":"Leach","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl Suppl 1","key":"zoi241271r44","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/pds.3822","article-title":"Do case-only designs yield consistent results across design and different databases? A case study of hip fractures and benzodiazepines.","volume":"25","author":"Requena","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"zoi241271r45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00223-020-00688-1","article-title":"Medications as a risk factor for fragility hip fractures: a systematic review and meta-analysis.","volume":"107","author":"Mortensen","year":"2020","journal-title":"Calcif Tissue Int"},{"key":"zoi241271r46","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2023.101866","article-title":"Sedative-hypnotics and osteoporotic fractures: a systematic review of observational studies with over six million individuals.","volume":"73","author":"Xu","year":"2024","journal-title":"Sleep Med Rev"},{"key":"zoi241271r47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijotn.2023.101078","article-title":"Association of tramadol use with risk of hip fractures in patients with osteoarthritis: a systematic review and meta-analysis of observational studies.","volume":"52","author":"Bahardoust","year":"2024","journal-title":"Int J Orthop Trauma Nurs"},{"issue":"4","key":"zoi241271r48","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1093\/ageing\/afaa249","article-title":"STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on fall-risk-increasing drugs.","volume":"50","author":"Seppala","year":"2021","journal-title":"Age Ageing"},{"issue":"2","key":"zoi241271r49","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1248\/bpb.b19-00737","article-title":"Central nervous system agent classes and fragility fracture risk among elderly Japanese individuals in a nationwide case-crossover design study.","volume":"43","author":"Ohara","year":"2020","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"zoi241271r50","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1001\/archneurol.2010.341","article-title":"Association of antiepileptic drugs with nontraumatic fractures: a population-based analysis.","volume":"68","author":"Jett\u00e9","year":"2011","journal-title":"Arch Neurol"},{"key":"zoi241271r51","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2147\/CLEP.S278306","article-title":"Hip fracture risk in antiepileptic drug initiators and non-initiators with Alzheimer\u2019s disease.","volume":"13","author":"Pisa","year":"2021","journal-title":"Clin Epidemiol"},{"issue":"5","key":"zoi241271r52","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1111\/bcpt.13825","article-title":"The risk of fragility fractures following initiation of gabapentin and pregabalin: a Danish, nationwide, high-dimensional propensity score-matched cohort study.","volume":"132","author":"J\u00f8rgensen","year":"2023","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"zoi241271r53","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/nrrheum.2009.260","article-title":"Osteoporosis: impact on health and economics.","volume":"6","author":"Harvey","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"zoi241271r54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/ageing\/afv166","article-title":"Use of a frailty index to identify potentially inappropriate prescribing and adverse drug reaction risks in older patients.","volume":"45","author":"Cullinan","year":"2016","journal-title":"Age Ageing"},{"issue":"4","key":"zoi241271r55","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1093\/ageing\/afy022","article-title":"Evaluating frailty scores to predict mortality in older adults using data from population based electronic health records: case control study.","volume":"47","author":"Stow","year":"2018","journal-title":"Age Ageing"},{"issue":"11","key":"zoi241271r56","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.41915","article-title":"Automated electronic frailty index-identified frailty status and associated postsurgical adverse events.","volume":"6","author":"Khanna","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi241271r57","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3389\/fpubh.2020.00089","article-title":"A computerized frailty assessment tool at points-of-care: development of a standalone electronic comprehensive geriatric assessment\/frailty index (eFI-CGA).","volume":"8","author":"Sepehri","year":"2020","journal-title":"Front Public Health"},{"issue":"1","key":"zoi241271r58","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s40261-016-0464-1","article-title":"Efficacy and safety of pregabalin for the treatment of neuropathic pain in patients undergoing hemodialysis.","volume":"37","author":"Otsuki","year":"2017","journal-title":"Clin Drug Investig"},{"issue":"3","key":"zoi241271r59","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.bja.2021.08.035","article-title":"Analgesic use and associated adverse events in patients with chronic kidney disease: a systematic review and meta-analysis.","volume":"128","author":"Lambourg","year":"2022","journal-title":"Br J Anaesth"},{"issue":"6","key":"zoi241271r60","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1681\/ASN.2019090904","article-title":"Hip fracture risk among hemodialysis-dependent patients prescribed opioids and gabapentinoids.","volume":"31","author":"Vangala","year":"2020","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"zoi241271r61","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1681\/ASN.2018010096","article-title":"Gabapentin and pregabalin use and association with adverse outcomes among hemodialysis patients.","volume":"29","author":"Ishida","year":"2018","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"zoi241271r63","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s11914-022-00750-x","article-title":"Effects of gabapentin and pregabalin on calcium homeostasis: implications for physical rehabilitation of musculoskeletal tissues.","volume":"20","author":"Reyes Fernandez","year":"2022","journal-title":"Curr Osteoporos Rep"},{"key":"zoi241271r64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fpain.2020.00001","article-title":"Neuropathic pain: challenges and opportunities.","volume":"1","author":"van Velzen","year":"2020","journal-title":"Front Pain Res (Lausanne)"},{"key":"zoi241271r5","unstructured":"IQVIA Institute for Human Data Science. Medicine use and spending in the U.S.\u2014a review of 2018 and outlook to 2023. 2019. Accessed October 9. 2024. https:\/\/www.iqvia.com\/insights\/the-iqvia-institute\/reports-and-publications\/reports\/medicine-use-and-spending-in-the-us-a-review-of-2018-and-outlook-to-2023"},{"key":"zoi241271r6","unstructured":"Australian Government Department of Health and Aged Care. Pharmaceutical Benefits Scheme (PBS) expenditure and prescriptions report 1 July 2022 to 30 June 2023. 2023. Accessed October 9. 2024. https:\/\/www.pbs.gov.au\/statistics\/expenditure-prescriptions\/2022-2023\/PBS-Expenditure-prescriptions-report-2022-23.pdf"},{"key":"zoi241271r38","unstructured":"Australian Institute of Health and Welfare. Chronic kidney disease: Australian facts. 2024. Accessed October 9, 2024. https:\/\/www.aihw.gov.au\/reports\/chronic-kidney-disease\/chronic-kidney-disease\/contents\/about"},{"key":"zoi241271r62","unstructured":"Australian Medicines Handbook (online). Australian Medicines Handbook Pty Ltd. Accessed October 9, 2024. https:\/\/amhonline.amh.net.au\/"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2826109\/leung_2024_oi_241271_1730759154.48325.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:37:09Z","timestamp":1731497829000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2826109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":64,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11,4]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.44488","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}